Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MGNX NASDAQ:MIST On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMGNXMacroGenics$3.14-2.0%$2.89$1.18▼$3.88$199.26M1.08998,974 shs321,982 shsMISTMilestone Pharmaceuticals$1.91+0.5%$1.68$1.00▼$3.06$222.99M1.042.27 million shs857,524 shs10 Best Stocks to Own in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Spring 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMGNXMacroGenics0.00%+2.62%+1.95%+78.86%+78.86%MISTMilestone Pharmaceuticals0.00%-0.27%+35.51%-5.08%+42.75%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMGNXMacroGenics$3.14-2.0%$2.89$1.18▼$3.88$199.26M1.08998,974 shs321,982 shsMISTMilestone Pharmaceuticals$1.91+0.5%$1.68$1.00▼$3.06$222.99M1.042.27 million shs857,524 shs10 Best Stocks to Own in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Spring 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMGNXMacroGenics0.00%+2.62%+1.95%+78.86%+78.86%MISTMilestone Pharmaceuticals0.00%-0.27%+35.51%-5.08%+42.75%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMGNXMacroGenics 2.25Hold$5.4072.25% UpsideMISTMilestone Pharmaceuticals 2.67Moderate Buy$7.50293.70% UpsideCurrent Analyst Ratings BreakdownLatest MGNX and MIST Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/20/2026MGNXMacroGenics BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$4.00 ➝ $6.004/10/2026MGNXMacroGenics B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$3.00 ➝ $9.004/10/2026MISTMilestone Pharmaceuticals Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageStrong-Buy$6.004/9/2026MISTMilestone Pharmaceuticals Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageStrong-Buy3/10/2026MGNXMacroGenics BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$3.00 ➝ $4.002/24/2026MGNXMacroGenics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Perform2/24/2026MISTMilestone Pharmaceuticals Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 5/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMGNXMacroGenics$149.50M1.33N/AN/A$0.88 per share3.56MISTMilestone Pharmaceuticals$1.55M144.62N/AN/A$0.39 per share4.88Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMGNXMacroGenics-$74.62M-$1.17N/AN/AN/A-49.91%-120.19%-29.92%5/12/2026 (Estimated)MISTMilestone Pharmaceuticals-$63.06M-$0.79N/AN/AN/AN/A-656.73%-81.19%5/13/2026 (Estimated)Latest MGNX and MIST EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026MISTMilestone Pharmaceuticals$0.19N/AN/AN/A$30.12 millionN/A5/12/2026Q1 2026MGNXMacroGenics-$0.56N/AN/AN/A$16.29 millionN/A3/20/2026Q4 2025MISTMilestone Pharmaceuticals-$0.18-$0.16+$0.02-$0.16$37.52 million$1.44 million3/9/2026Q4 2025MGNXMacroGenics-$0.42-$0.2241+$0.1959-$0.22$27.81 million$41.23 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthMGNXMacroGenicsN/AN/AN/AN/AN/AMISTMilestone PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMGNXMacroGenicsN/A5.104.92MISTMilestone Pharmaceuticals1.378.017.96Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMGNXMacroGenics96.89%MISTMilestone Pharmaceuticals86.18%Insider OwnershipCompanyInsider OwnershipMGNXMacroGenics13.60%MISTMilestone Pharmaceuticals19.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMGNXMacroGenics43063.56 million54.92 millionOptionableMISTMilestone Pharmaceuticals30117.67 million94.72 millionOptionableMGNX and MIST HeadlinesRecent News About These CompaniesMilestone Pharmaceuticals Inc. (NASDAQ:MIST) Short Interest UpdateApril 30, 2026 | marketbeat.comMilestone Pharmaceuticals Inc. (NASDAQ:MIST) Receives Average Rating of "Moderate Buy" from AnalystsApril 24, 2026 | marketbeat.comInsider Selling: Milestone Pharmaceuticals (NASDAQ:MIST) CEO Sells 36,500 Shares of StockApril 21, 2026 | insidertrades.comJoseph Oliveto Sells 36,500 Shares of Milestone Pharmaceuticals (NASDAQ:MIST) StockApril 20, 2026 | marketbeat.comMilestone Pharmaceuticals (NASDAQ:MIST) Upgraded to Strong-Buy at Raymond James FinancialApril 11, 2026 | marketbeat.comMilestone Pharmaceuticals (NASDAQ:MIST) Lowered to "Sell" Rating by Wall Street ZenApril 11, 2026 | marketbeat.comRaymond James Financial Initiates Coverage on Milestone Pharmaceuticals (NASDAQ:MIST)April 10, 2026 | marketbeat.comMilestone Pharmaceuticals Announces RESET-PSVT Registry to Generate Real-World Evidence on CARDAMYST™ (etripamil) Nasal Spray in Patients With PSVTApril 10, 2026 | globenewswire.comMilestone's nasal spray heart drug available via Express ScriptsApril 7, 2026 | ncbiotech.orgNMilestone Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare ConferenceApril 7, 2026 | globenewswire.comMilestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 2, 2026 | globenewswire.comMilestone Pharmaceuticals Announces that CARDAMYST™ (etripamil) Nasal Spray is Available on Express Scripts Commercial National FormulariesMarch 31, 2026 | globenewswire.comMilestone Pharmaceuticals Inc. (MIST) Q4 2025 Earnings Call TranscriptMarch 20, 2026 | seekingalpha.comMilestone Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST™ (etripamil) Nasal Spray for ...March 20, 2026 | finance.yahoo.comMilestone Pharmaceuticals Inc (MIST) Q4 2025 Earnings Call Highlights: Strategic Advances Amid ...March 20, 2026 | finance.yahoo.comWhy Milestone Pharma Stock Is Taking A Dive TodayMarch 20, 2026 | benzinga.comMilestone Pharmaceuticals Announces FDA Approval of CARDAMYST™, the First New Treatment for PSVT in 30 YearsMarch 20, 2026 | quiverquant.comQMilestone Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST™ (etripamil) Nasal Spray for the Treatment of PSVTMarch 20, 2026 | globenewswire.comMilestone Pharmaceuticals Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate AnalystsMarch 20, 2026 | benzinga.comMilestone Pharmaceuticals Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate AnalystsMarch 20, 2026 | benzinga.comMilestone Pharmaceuticals to Present Data on CARDAMYST™ (etripamil) Nasal Spray at the 2026 American College of Cardiology Annual Scientific SessionMarch 16, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMGNX and MIST Company DescriptionsMacroGenics NASDAQ:MGNX$3.14 -0.07 (-2.03%) As of 02:30 PM Eastern This is a fair market value price provided by Massive. Learn more.MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.Milestone Pharmaceuticals NASDAQ:MIST$1.90 +0.01 (+0.53%) As of 02:30 PM Eastern This is a fair market value price provided by Massive. Learn more.Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas onsemi Stock Dips After Earnings: Why the Dip Is Buyable Nebius Breaks Out to All-Time Highs—Here's What's Driving It. 3 Reasons Analysts Love DexCom Atomic Dividends: Big Tech's New Energy Bet Monolithic Power Systems: AI Stock Beat, Raised and Upgraded Post-Earnings Leading Insider Sales: April Activity Ramps in These Stocks The New Fed Chair Trade: Who Wins When Warsh Takes the Helm? A Prada Payday: Is AMC Back in Style? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
